Srinath Kasturirangan
Overview
Explore the profile of Srinath Kasturirangan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jung P, Glaser S, Han J, Popa A, Pisarsky L, Feng N, et al.
MAbs
. 2024 Dec;
16(1):2438173.
PMID: 39654063
Exploitation of extrinsic apoptosis signaling via TRAILR2 activation represents a promising therapeutic concept in cancer treatment. The limited clinical success of previous TRAILR2 agonistic agents, to date, has been ascribed...
2.
Aertker K, Ravindra Pilvankar M, Prass T, Blech M, Higel F, Kasturirangan S
MAbs
. 2024 Mar;
16(1):2318817.
PMID: 38444390
Bispecific antibodies (BsAbs) capable of recognizing two distinct epitopes or antigens offer promising therapeutic options for various diseases by targeting multiple pathways. The favorable pharmacokinetic (PK) properties of monoclonal antibodies...
3.
Liu Y, Tsang K, Mays M, Hansen G, Chiecko J, Crames M, et al.
MAbs
. 2022 May;
14(1):2073632.
PMID: 35613320
Biotherapeutic optimization, whether to improve general properties or to engineer specific attributes, is a time-consuming process with uncertain outcomes. Conversely, Consensus Protein Design has been shown to be a viable...
4.
Manikwar P, Mulagapati S, Kasturirangan S, Moez K, Rainey G, Lobo B
J Pharm Sci
. 2019 Jul;
109(1):220-232.
PMID: 31288034
Bispecific antibodies containing single-chain variable fragment (scFv) appended to immunoglobulins G offer unique development challenges. Here, we describe the stability of a novel bispecific format, BiS5, where the scFv is...
5.
Kasturirangan S, Rainey G, Xu L, Wang X, Portnoff A, Chen T, et al.
J Biol Chem
. 2017 Jan;
292(10):4361-4370.
PMID: 28100773
Soluble ligands have commonly been targeted by antibody therapeutics for cancers and other diseases. Although monoclonal antibodies targeting such ligands can block their interactions with their cognate receptors, they can...
6.
Devanaboyina S, Lynch S, Ober R, Ram S, Kim D, Puig-Canto A, et al.
MAbs
. 2014 Feb;
5(6):851-9.
PMID: 24492341
A drawback of targeting soluble antigens such as cytokines or toxins with long-lived antibodies is that such antibodies can prolong the half-life of the target antigen by a "buffering" effect....
7.
Kasturirangan S, Reasoner T, Schulz P, Boddapati S, Emadi S, Valla J, et al.
Biotechnol Prog
. 2013 Jan;
29(2):463-71.
PMID: 23359572
We developed atomic force microscope (AFM)-based protocols that enable isolation and characterization of antibody-based reagents that selectively bind target protein variants using low nanogram amounts or less of unpurified starting...
8.
Boddapati S, Levites Y, Suryadi V, Kasturirangan S, Sierks M
J Alzheimers Dis
. 2011 Dec;
28(4):961-9.
PMID: 22156046
Misfolding and aggregation of amyloid-β (Aβ) is an important early event in the pathogenesis of Alzheimer's disease. Aβ is produced by sequential proteolysis of the amyloid-β protein precursor (AβPP) by...
9.
Sierks M, Chatterjee G, McGraw C, Kasturirangan S, Schulz P, Prasad S
Integr Biol (Camb)
. 2011 Nov;
3(12):1188-96.
PMID: 22076255
Protein misfolding and aggregation is a critically important feature in many devastating neurodegenerative diseases, therefore characterization of the CSF concentration profiles of selected key forms and morphologies of proteins involved...
10.
Kasturirangan S, Li L, Emadi S, Boddapati S, Schulz P, Sierks M
Neurobiol Aging
. 2010 Nov;
33(7):1320-8.
PMID: 21067847
While accumulation and deposition of beta amyloid (Aβ) is a primary pathological feature of Alzheimer's disease (AD), increasing evidence has implicated small, soluble oligomeric aggregates of Aβ as the neurotoxic...